Avita Medical, Inc. · NASDAQ:RCEL
Avita Medical — Q2 2026 Earnings Presentation
12 slides from Avita Medical's earnings presentation, Aug 10, 2026
Slide 1: AVITA Medical Second Quarter 2026 Briefing
For personal use only August 2026 AVITA Medical Second Quarter 2026 Briefing (ASX: AVH, NASDAQ: RCEL)
Slide 2: Forward-Looking Statements & Legal Disclaimers
Forward-Looking Statements & Legal Disclaimers 2024.Q4 v9 This presentation and the accompanying oral commentary may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These For personal use only statements are predictions and subject to si
Slide 3: AVITA's focused strategy is delivering results with an attractive growth profile
AVITA’s focused strategy is delivering results with an attractive growth profile Net revenue Portfolio quarter-over-quarter For personal use only in USD millions in USD millions Q1 2026 Q2 2026 US RECELL $16.6 $18.5 ~11% Int RECELL $0.7 $0.9 ~26% $18.4 $17.1 $17.6 $19.3 $21.7 Cohealyx $1.5 $1.7 ~16%
Slide 4: Revenue growth continues to lead positive change in financials
Revenue growth continues to lead positive change in financials Change vs PY Q1 For personal use only Key figures Q2 Q2 Change vs Q1 in USD millions 2026 2025 2026 Revenue $21.7 $18.4 +18% $19.3 +13% Gross profit margin 81.9% 81.2% +70 BPS 81.7% +20 BPS Operating expenses $24.6 $26.1 +5.8% $24.5 n/a
Slide 5: Clear trajectory to cash flow breakeven in 2026
Clear trajectory to cash flow breakeven in 2026 Revenue Growth Gross margin Operating Expense For personal use only in USD millions in USD millions Full year forecast: $21.7 $86-89 $24.7 $24.5 $24.6 $19.3 81.2% 81.7% 81.9% $17.6 ~13% QoQ ~10% Q4 Q1 Q2 Q4 Q1 Q2 QoQ 2025 2025 Q4 Q1 Q2 2025 Sequential
Slide 6: Balance sheet supports our 2026 outlook
Balance sheet supports our 2026 outlook Updated full year 2026 guidance For personal use only Net Revenue expected to grow: Expect to achieve cash flow breakeven in: $86M to $89M Q4 2026 Balance sheet outlook Liquidity Covenant Confidence Financial Flexibility Liquidity supports Minimum cash and tra
Slide 7: RECELL remains our key product with broadening growth
RECELL remains our key product with broadening growth RECELL: Repigmentation in a full face deep RECELL volume rose ~11% in 2Q26, with RECELL GO partial-thickness burn | 31-year-old female mini driving incremental growth in smaller wounds For personal use only Treatment Day Day 9 1 Year New provider
Slide 8: New 2027 SCSA CPT Code family streamlines RECELL procedure reporting
New 2027 SCSA CPT Code family streamlines RECELL procedure reporting 2027 SCSA CPT Code family improves coding clarity and supports proposed national physician valuation framework For personal use only Key improvements in the new code structure Bundles harvest, preparation, and application Why the v
Slide 9: Layering AVITA's products across case complexity drives higher revenue
Layering AVITA’s products across case complexity drives higher revenue Illustrative For personal use only Partial-Thickness Wound Deep Partial-Thickness Wound Full-Thickness Wound Epidermis Dermis Full thickness ~$2,160 ~$17,160 ~$57,480 Example is based on a 15% Total Body Surface Area burn (= 2,88
Slide 10: AVITA's integrated offering is well aligned with provider incentives
AVITA’s integrated offering is well aligned with provider incentives to reduce LOS, improve outcomes, and manage costs RECELL supports significantly Cohealyx supports faster graft- PermeaDerm provides an alternative shorter hospital length of stay (LOS) readiness to allograft / cadaver skin For pers
Slide 11: We are built to grow
We are built to grow For personal use only AVITA Medical’s focused Our growth profile Robust data and commercial strategy is delivering results is attractive capabilities Delivered +13% QoQ increase Raised 2026 revenue forecast Portfolio is well aligned with in revenue with broad based to $86 to $89
Slide 12: For personal use only
For personal use only